ADVENZYMES Advanced Enzyme Technologies Q4 FY25 results (Jan–Mar 2025) and concall
Advanced Enzyme Technologies reported a 6% YoY revenue growth in Q4 FY25 to INR 1,672 million, with full-year FY25 revenue growing 2% to INR 6,369 million. However, Q4 EBITDA margin compressed to 27% due to product mix and inventory valuation adjustments. The company highlighted increased R&D spend, strong growth in Specialized Manufacturing, and progress in sustainability initiatives. Management anticipates mid-double-digit revenue growth for FY26, driven by biocatalysts and animal feed, while addressing challenges in Human Nutrition and competitive pressures on key products.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 77 | 101 | 87 |
| EBITDA | 14 | 22 | 14 |
| Net profit | 9 | 15 | 11 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
